/ASRT
ASRT Stock - Assertio Holdings, Inc.
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$9.32+1.47%
+$0.14 (+1.47%) • Jan 12
33
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.SELL
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.15
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).0
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.95
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-81.2%upside
Target: $1.75
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ASRT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$9.23 – $9.41
TARGET (TP)$1.75
STOP LOSS$8.57
RISK/REWARD1:-10.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.61
52W High$15.15
52W Low$7.65
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $124.96M | $152.07M | $156.23M | $111.01M | $108.08M |
| Gross Profit | $85.73M | $125.05M | $137.49M | $95.18M | $92.30M |
| Gross Margin | 68.6% | 82.2% | 88.0% | 85.7% | 85.4% |
| Operating Income | $-24,476,000 | $-243,536,000 | $39.41M | $9.42M | $-82,155,000 |
| Net Income | $-21,581,000 | $-331,942,000 | $109.63M | $-1,281,000 | $-28,144,000 |
| Net Margin | -17.3% | -218.3% | 70.2% | -1.2% | -26.0% |
| EPS | $-3.45 | $-70.05 | $34.95 | $-0.45 | $-16.05 |
Company Overview
Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
3 Bullish0 Neutral/Bearish
Price Targets
$5
Average Target
↓ 49.9% Downside
Now
$3
Low
$5
Average
$7
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 26th 2024 | Maxim Group | Initiation | Buy | $3 |
| July 3rd 2024 | H.C. Wainwright | Initiation | Buy | $4 |
| November 7th 2022 | Lake Street | Initiation | Buy | $7 |
Earnings History & Surprises
ASRTBeat Rate
44%
Last 18 quarters
Avg Surprise
+181.2%
EPS vs Estimate
Beats / Misses
8/10
Last 12 quarters
Latest EPS
$0.11
Q4 2025
EPS Surprise History
Q1 24
+2949.7%
$0.11vs$-0.00
Q2 24
-66.7%
$0.04vs$0.12
Q3 24
-25.0%
$-0.04vs$-0.03
Q4 24
+40.0%
$-0.03vs$-0.05
Q1 25
-120.0%
$-0.11vs$-0.05
Q2 25
-133.3%
$-0.14vs$-0.06
Q3 25
-70.0%
$-0.17vs$-0.10
Q4 25
+237.5%
$0.11vs$-0.08
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 11, 2026 | $-3.00 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.08 | $0.11 | +237.5% | ✓ BEAT |
Q3 2025 | Aug 11, 2025 | $-0.10 | $-0.17 | -70.0% | ✗ MISS |
Q2 2025 | May 12, 2025 | $-0.06 | $-0.14 | -133.3% | ✗ MISS |
Q1 2025 | Mar 12, 2025 | $-0.05 | $-0.11 | -120.0% | ✗ MISS |
Q4 2024 | Nov 11, 2024 | $-0.05 | $-0.03 | +40.0% | ✓ BEAT |
Q3 2024 | Aug 7, 2024 | $-0.03 | $-0.04 | -25.0% | ✗ MISS |
Q2 2024 | May 6, 2024 | $0.12 | $0.04 | -66.7% | ✗ MISS |
Q1 2024 | Mar 11, 2024 | $-0.00 | $0.11 | +2949.7% | ✓ BEAT |
Q4 2023 | Nov 8, 2023 | $0.14 | $0.01 | -92.9% | ✗ MISS |
Q3 2023 | Aug 3, 2023 | $0.14 | $0.13 | -7.1% | ✗ MISS |
Q2 2023 | May 9, 2023 | $0.13 | $-0.07 | -153.8% | ✗ MISS |
Q1 2023 | Mar 8, 2023 | $0.23 | $1.34 | +482.6% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $0.07 | $0.08 | +14.3% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $0.08 | $0.16 | +100.0% | ✓ BEAT |
Q2 2022 | May 9, 2022 | $0.09 | $0.20 | +122.2% | ✓ BEAT |
Q1 2022 | Mar 9, 2022 | $0.12 | $0.10 | -16.7% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $0.02 | $0.08 | +300.0% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-0.08 | $-0.32 | -300.0% | ✗ MISS |
Latest News
Assertio Holdings Regains Compliance With All Applicable Nasdaq Listing Requirements
📈 PositiveBenzinga•Jan 12, 2026, 09:15 PM
Assertio Data From Clinical Study Of Rolvedon Injection Demonstrates Effective Neutrophil Recovery
📈 PositiveBenzinga•Jan 9, 2026, 06:50 PM
HC Wainwright & Co. Maintains Buy on Assertio Holdings, Raises Price Target to $35
📈 PositiveBenzinga•Jan 5, 2026, 12:23 PM
Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Dec 26, 2025, 01:55 PM
Trading Halt: Halted at 4:50:00 p.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Dec 24, 2025, 09:50 PM
Assertio Holdings, Inc. Announces 1-for-15 Reverse Stock Split, Effective Dec. 26
➖ NeutralBenzinga•Dec 22, 2025, 09:31 PM
Assertio stock rises after revenue beat
📈 PositiveSeeking Alpha•Nov 10, 2025, 09:53 PM
Assertio Holdings shares are trading higher after the company reported better-than-expected Q3 financial results.
📈 PositiveBenzinga•Nov 10, 2025, 09:20 PM
Assertio Holdings Narrows FY2025 Sales Guidance from $108.000M-$118.000M to $110.000M-$112.000M vs $111.089M Est
➖ NeutralBenzinga•Nov 10, 2025, 09:15 PM
Assertio Holdings Q3 Adj. EPS $0.18 Beats $(0.09) Estimate, Sales $49.459M Beat $27.020M Estimate
📈 PositiveBenzinga•Nov 10, 2025, 09:14 PM
Assertio Appoints Mark L. Reisenauer As CEO, Effective Immediately, Succeeding Brendan P.
➖ NeutralBenzinga•Oct 28, 2025, 01:16 PM
Assertio Presents Data On SYMPAZAN Showing How It is Being Used In Daily Clinical Practice To Treat Patients With Lennox-gastaut Syndrome
📈 PositiveBenzinga•Sep 15, 2025, 01:04 PM
Assertio Holdings Will Present New Data For Sympazan (Clobazam) At The Annual Meeting Of The American Neurological Association
📈 PositiveBenzinga•Sep 10, 2025, 11:32 AM
Reuters Reports FDA Saying Assertio Specialty Pharmaceuticals Discontinues Manufacturing Of Otrexup, Injection
📉 NegativeBenzinga•Aug 29, 2025, 01:58 PM
Assertio Holdings Non-GAAP EPS of $0.02 beats by $0.03, revenue of $29.22M beats by $1.25M
📈 PositiveSeeking Alpha•Aug 11, 2025, 08:11 PM
Frequently Asked Questions about ASRT
What is ASRT's current stock price?
Assertio Holdings, Inc. (ASRT) is currently trading at $9.32 per share. The stock has moved +1.47% today.
What is the analyst price target for ASRT?
The average analyst price target for ASRT is $1.75, based on 1 analyst.
What sector is Assertio Holdings, Inc. in?
Assertio Holdings, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is ASRT's market cap?
Assertio Holdings, Inc. has a market capitalization of $0.06 billion, making it a small-cap company.
Does ASRT pay dividends?
No, Assertio Holdings, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACRV
Acrivon Therapeutics, Inc. Common Stock
$1.63
Mkt Cap: $0.1B
FBIO
Fortress Biotech, Inc.
$4.20
Mkt Cap: $0.1B
INCR
InterCure Ltd.
$0.99
Mkt Cap: $0.1B
LITS
Lite Strategy, Inc.
$1.45
Mkt Cap: $0.1B
LUNG
Pulmonx Corporation
$1.99
Mkt Cap: $0.1B
NTRB
Nutriband Inc.
$4.22
Mkt Cap: $0.0B
PMVP
PMV Pharmaceuticals, Inc.
$1.17
Mkt Cap: $0.1B
TCRX
TScan Therapeutics, Inc.
$1.17
Mkt Cap: $0.1B
VXRT
Vaxart, Inc.
$0.80
Mkt Cap: $0.2B
XBIT
XBiotech Inc.
$2.53
Mkt Cap: $0.1B
Explore stocks similar to ASRT for comparison